应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06185 康希诺生物
劳动节休市 04-30 16:08:17
33.950
+3.550
+11.68%
最高
34.750
最低
30.700
成交量
331.53万
今开
30.700
昨收
30.400
日振幅
13.32%
总市值
84.01亿
流通市值
45.15亿
总股本
2.47亿
成交额
1.10亿
换手率
2.49%
流通股本
1.33亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
康希诺生物午后涨超13% 一季度营收同比增长20%
DoNews · 04-30 13:55
康希诺生物午后涨超13% 一季度营收同比增长20%
康希诺生物午后上涨逾13% 一季度营业收入同比增加20%
新浪港股 · 04-30 13:38
康希诺生物午后上涨逾13% 一季度营业收入同比增加20%
港股异动 | 康希诺生物(06185)盘中涨超10% 曼海欣市占率不断提升 一季度营收同比增20%
智通财经 · 04-30 11:52
港股异动 | 康希诺生物(06185)盘中涨超10% 曼海欣市占率不断提升 一季度营收同比增20%
港股异动 | 生物技术股走强,康希诺生物涨超10%
老虎资讯综合 · 04-30 11:13
港股异动 | 生物技术股走强,康希诺生物涨超10%
港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(099
美港电讯 · 04-30 11:11
港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(099
异动解读 | 康希诺生物盘中大涨5.43%,一季度业绩大幅减亏
异动解读 · 04-30 10:32
异动解读 | 康希诺生物盘中大涨5.43%,一季度业绩大幅减亏
康希诺生物盘中异动 早盘股价大涨5.26%报32.000港元
市场透视 · 04-30 10:06
康希诺生物盘中异动 早盘股价大涨5.26%报32.000港元
康希诺:一季度净利润亏损1154.54万元 同比大幅减亏
E公司 · 04-29 17:57
康希诺:一季度净利润亏损1154.54万元 同比大幅减亏
康希诺生物04月25日遭主力抛售9万元
市场透视 · 04-25
康希诺生物04月25日遭主力抛售9万元
港股异动 | 生物医药板块持续高开,康方生物涨5%,本周已累涨近30%
老虎资讯综合 · 04-25
港股异动 | 生物医药板块持续高开,康方生物涨5%,本周已累涨近30%
康希诺生物04月23日获主力加仓24万元
市场透视 · 04-23
康希诺生物04月23日获主力加仓24万元
康希诺生物拟4月29日举行董事会会议审批一季度业绩
格隆汇 · 04-15
康希诺生物拟4月29日举行董事会会议审批一季度业绩
全国政协委员、康希诺生物首席科学官朱涛:我国正处于疫苗研发的“黄金十年”,免疫规划体系将持续完善
21经济网 · 03-10
全国政协委员、康希诺生物首席科学官朱涛:我国正处于疫苗研发的“黄金十年”,免疫规划体系将持续完善
康希诺朱涛:mRNA肿瘤疫苗是布局方向,国家免疫规划扩容需考虑供应稳定性
澎湃新闻 · 03-09
康希诺朱涛:mRNA肿瘤疫苗是布局方向,国家免疫规划扩容需考虑供应稳定性
智通AH统计|3月7日
智通财经 · 03-07
智通AH统计|3月7日
康希诺生物盘中异动 大幅上涨5.00%
市场透视 · 03-06
康希诺生物盘中异动 大幅上涨5.00%
康希诺生物03月04日遭主力抛售170万元
市场透视 · 03-04
康希诺生物03月04日遭主力抛售170万元
全国政协委员、康希诺生物首席科学官朱涛:希望通过政策优化医药创新生态 支持医药创新成果转化
每日经济新闻 · 03-04
全国政协委员、康希诺生物首席科学官朱涛:希望通过政策优化医药创新生态 支持医药创新成果转化
康希诺:mRNA技术平台可应用于多类生物制品的开发,包括肿瘤领域及免疫治疗也可以是拓展方向
互动易 · 03-03
康希诺:mRNA技术平台可应用于多类生物制品的开发,包括肿瘤领域及免疫治疗也可以是拓展方向
加载更多
公司概况
公司名称:
康希诺生物
所属市场:
SEHK
上市日期:
--
主营业务:
康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。
发行价格:
--
{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":33.95,"timestamp":1746000497036,"preClose":30.4,"halted":0,"volume":3315300,"delay":0,"floatShares":133000000,"shares":247449899,"eps":-1.6327634079187188,"marketStatus":"劳动节休市","change":3.55,"latestTime":"04-30 16:08:17","open":30.7,"high":34.75,"low":30.7,"amount":110301815,"amplitude":0.133224,"askPrice":33.95,"askSize":151800,"bidPrice":33.75,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-1.6327634079187188,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":7,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":30.4,"dividendRate":0.0266,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"volumeRatio":4.050921,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":56.85,"timestamp":1745996400000,"preClose":54.49,"halted":0,"volume":1823900,"delay":0,"premium":"-44.04"}},"requestUrl":"/m/hq/s/06185","defaultTab":"news","newsList":[{"id":"2531797907","title":"康希诺生物午后涨超13% 一季度营收同比增长20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531797907","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531797907?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:55","pubTimestamp":1745992502,"startTime":"0","endTime":"0","summary":"4月30日,康希诺生物(06185)午后股价上涨12.66%,报34.25港元,成交额达7482.74万港元。公司第一季度报告显示,按中国会计准则,实现营业收入1.37亿元人民币,同比增长20.02%。亏损从上年同期的1.7亿元大幅收窄至1155万元。其四价流脑结合疫苗曼海欣市场占有率持续提升,推动业绩增长。免责声明:本文内容由开放的智能模型自动生成,仅供参考。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135633974b225d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430135633974b225d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185","688185"],"gpt_icon":0},{"id":"2531776120","title":"康希诺生物午后上涨逾13% 一季度营业收入同比增加20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531776120","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531776120?lang=zh_cn&edition=full","pubTime":"2025-04-30 13:38","pubTimestamp":1745991480,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 康希诺生物(06185)午后持续上涨12.66%,现报34.25港元,成交额7482.74万港元。\n 康希诺生物公布第一季度报告,按中国会计准则,实现营业收入1.37亿人民币,同比增加20%。亏损由上年同期1.7亿,大幅收窄至1155万元。曼海欣作为中国市场上唯一的四价流脑结合疫苗,市场占有率不断提升,促使本期实现营业收入1.37亿元,同比增长20.02%。\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-04-30/doc-ineuxmqz4322343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06185"],"gpt_icon":0},{"id":"2531272411","title":"港股异动 | 康希诺生物(06185)盘中涨超10% 曼海欣市占率不断提升 一季度营收同比增20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531272411","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531272411?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:52","pubTimestamp":1745985178,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,康希诺生物盘中涨超10%,截至发稿,涨9.38%,报33.25港元,成交额4845.1万港元。消息面上,康希诺生物公布第一季度报告,按中国会计准则,实现营业收入1.37亿人民币,同比增加20%。亏损由上年同期1.7亿,大幅收窄至1155万元。曼海欣作为中国市场上唯一的四价流脑结合疫苗,市场占有率不断提升,促使本期实现营业收入1.37亿元,同比增长20.02%。中信建投此前指出,康希诺生物2024年业绩符合预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06185"],"gpt_icon":0},{"id":"1156609182","title":"港股异动 | 生物技术股走强,康希诺生物涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156609182","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156609182?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:13","pubTimestamp":1745982808,"startTime":"0","endTime":"0","summary":"4月30日,港股生物技术股盘中走强,$康希诺生物(06185)$涨超10%,$百济神州(06160$涨超6%,$诺诚健华(09969)$涨超4%,$泰格医药(03347)$涨超3%。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185","03347","06160","09969"],"gpt_icon":0},{"id":"2531726021","title":"港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(099","url":"https://stock-news.laohu8.com/highlight/detail?id=2531726021","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531726021?lang=zh_cn&edition=full","pubTime":"2025-04-30 11:11","pubTimestamp":1745982713,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1576","BK1500","HSTECH","BK0028","BK0077","688428","LU0588546209.SGD","BK1588","06160","06185","LU1820825898.SGD","LU1969619763.USD","LU2328871848.SGD","BK0216","BK4614","BK4139","BK1141","BK1515","BK1574","09969","300347","07226","YANG","688235","LU1146622755.USD","ONC","BK1583","BK0239","BK1161","HSCEI","03347","LU0307460666.USD","BK1191","BK0174"],"gpt_icon":0},{"id":"1112759415","title":"异动解读 | 康希诺生物盘中大涨5.43%,一季度业绩大幅减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=1112759415","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112759415?lang=zh_cn&edition=full","pubTime":"2025-04-30 10:32","pubTimestamp":1745980344,"startTime":"0","endTime":"0","summary":"4月30日周三盘中,康希诺生物(06185.HK)股价出现显著上涨,涨幅达5.43%,引发市场关注。\n\n据最新公布的一季度财报显示,康希诺生物净亏损为1154.54万元,相比去年同期出现大幅减亿。这一业绩改善可能是推动股价上涨的主要因素。投资者对公司经营状况的改善表现出积极反应,推动了股价的上涨。\n\n值得注意的是,机构投资者对康希诺生物保持看好态度。在参与评级的10家机构中,100%给予买入建议,显示出市场对该公司未来发展前景的信心。此外,康希诺生物所在的生物技术行业整体呈现上涨趋势,行业内多只个股表现活跃,进一步支撑了康希诺生物的股价走势。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 康希诺生物盘中大涨5.43%,一季度业绩大幅减亏","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06185"],"gpt_icon":0},{"id":"2531436728","title":"康希诺生物盘中异动 早盘股价大涨5.26%报32.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531436728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531436728?lang=zh_cn&edition=full","pubTime":"2025-04-30 10:06","pubTimestamp":1745978797,"startTime":"0","endTime":"0","summary":"2025年04月30日早盘10时06分,康希诺生物股票出现异动,股价大幅上涨5.26%。截至发稿,该股报32.000港元/股,成交量42.32万股,换手率0.32%,振幅4.28%。资金方面,该股资金流入634.6万港元,流出544.969万港元。康希诺生物股票所在的生物技术行业中,整体涨幅为0.27%。其相关个股中,乐普生物-B、百济神州、康希诺生物涨幅较大,振幅较大的相关个股有乐普生物-B、科伦博泰生物-B、歌礼制药-B,振幅分别为8.70%、7.35%、5.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430100637a46cfd0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430100637a46cfd0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688185","06185"],"gpt_icon":0},{"id":"2531202871","title":"康希诺:一季度净利润亏损1154.54万元 同比大幅减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2531202871","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531202871?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:57","pubTimestamp":1745920661,"startTime":"0","endTime":"0","summary":"人民财讯4月29日电,康希诺(688185)4月29日晚间发布一季报,2025年第一季度营收为1.37亿元,同比增长20.02%;净利润亏损1154.54万元,上年同期净亏损1.7亿元。曼海欣®作为中国市场上唯一的四价流脑结合疫苗,市场占有率不断提升,促使本期实现营业收入1.37亿元,同比增长20.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429175741a6cd0f92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429175741a6cd0f92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688185","06185"],"gpt_icon":0},{"id":"2530903191","title":"康希诺生物04月25日遭主力抛售9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530903191","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530903191?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:16","pubTimestamp":1745569007,"startTime":"0","endTime":"0","summary":"04月25日, 康希诺生物股价跌0.32%,报收30.80元,成交金额2953万元,换手率0.72%,振幅3.56%,量比0.96。康希诺生物今日主力资金净流出9万元,上一交易日主力净流出66万元。该股近5个交易日上涨7.50%,主力资金累计净流出122万元;近20日主力资金累计净流入1838万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170751a4669399&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425170751a4669399&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185","BK1191","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"1166357920","title":"港股异动 | 生物医药板块持续高开,康方生物涨5%,本周已累涨近30%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166357920","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166357920?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:27","pubTimestamp":1745544452,"startTime":"0","endTime":"0","summary":"本周五(4月25日)港股盘初,生物医药板块持续高开, $康方生物(09926)$ 涨5%,本周已累涨近30%, $云顶新耀-B(01952)$ 涨近5%:","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","03759","06606","09995","06185","00241","06160","01801","06618","06622","06127","06996","02269","02696","02359"],"gpt_icon":0},{"id":"2529578497","title":"康希诺生物04月23日获主力加仓24万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529578497","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529578497?lang=zh_cn&edition=full","pubTime":"2025-04-23 16:16","pubTimestamp":1745396216,"startTime":"0","endTime":"0","summary":"04月23日, 康希诺生物股价涨0.81%,报收30.95元,成交金额3285万元,换手率0.80%,振幅3.09%,量比0.97。康希诺生物今日主力资金净流入24万元,上一交易日主力净流入427万元。该股近5个交易日上涨2.31%,主力资金累计净流出341万元;近20日主力资金累计净流入1899万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423171301a463adb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423171301a463adb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1161","06185","BK1191"],"gpt_icon":0},{"id":"2527463497","title":"康希诺生物拟4月29日举行董事会会议审批一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2527463497","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527463497?lang=zh_cn&edition=full","pubTime":"2025-04-15 16:50","pubTimestamp":1744707035,"startTime":"0","endTime":"0","summary":"格隆汇4月15日丨康希诺生物(06185.HK)宣布,董事会会议将于2025年4月29日(星期二)举行,藉以(其中包括)考虑及批准公司及其附属公司截至2025年3月31日止三个月的第一季度业绩及其发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041516503694d5e503&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025041516503694d5e503&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","06185","BK1161","BK1191","BK1574"],"gpt_icon":0},{"id":"2518137012","title":"全国政协委员、康希诺生物首席科学官朱涛:我国正处于疫苗研发的“黄金十年”,免疫规划体系将持续完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2518137012","media":"21经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518137012?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:37","pubTimestamp":1741595820,"startTime":"0","endTime":"0","summary":"然而,随着疫苗种类的增多,传染病种类的变化,扩大免疫规划疫苗种类的呼声越来越高。全国政协委员、康希诺生物首席科学官朱涛在接受南方财经全媒体集团全国两会报道组记者采访时表示,从2020年往后十年,可以说是疫苗供应端、研发端的“黄金十年”,一系列的品种都有望在这10年上市。朱涛表示,具体纳入哪些疫苗,要计算纳入疫苗以后对公共卫生有多大受益。2021年,康希诺生物的4价流脑结合疫苗获批,又填补了一项空白。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031016461598a25800&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031016461598a25800&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","06185","688185","BK1574","BK1161"],"gpt_icon":0},{"id":"2518471790","title":"康希诺朱涛:mRNA肿瘤疫苗是布局方向,国家免疫规划扩容需考虑供应稳定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2518471790","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518471790?lang=zh_cn&edition=full","pubTime":"2025-03-09 08:35","pubTimestamp":1741480551,"startTime":"0","endTime":"0","summary":"mRNA技术平台可应用于多类生物制品的开发,包括肿瘤领域及免疫治疗也可以是拓展方向。近两年,呼吁将某些二类疫苗纳入国家免疫规划的声音不断出现。对此,朱涛认为,具体纳入哪些疫苗或者先纳入哪一个,背后需要详细的计算,纳入后到底能带来多大的公共卫生收益,这不仅要考虑价格,还要考虑供应的稳定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309085913a2675d92&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309085913a2675d92&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","688185","06185","BK1161","BK1191"],"gpt_icon":0},{"id":"2517740691","title":"智通AH统计|3月7日","url":"https://stock-news.laohu8.com/highlight/detail?id=2517740691","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517740691?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:15","pubTimestamp":1741335307,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示,截止3月7日收盘,东北电气、安德利果汁、弘业期货分列AH溢价率前三位,溢价率分别为864.29%、328.78%、325.29%;招商银行、药明康德、美的集团分列AH溢价率末三位,溢价率分别为7.49%、13.27%、16.50%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02727","002594","02359","06127","01349","03145","399300","03678","00187","02628","01877","06881","02883","00995","00553","02338","BYDDY","02218","00300","01812","02899","06690","82318","01658","06680","688981","06185","03968","01057","159982","601318","01033","00177","00042","03143","BK1119","00347","03606","HYDD.SI","PNGAY","HPAD.SI","01528","01330","LU2048586759.USD","81211","00568"],"gpt_icon":1},{"id":"2517777972","title":"康希诺生物盘中异动 大幅上涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517777972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517777972?lang=zh_cn&edition=full","pubTime":"2025-03-06 09:40","pubTimestamp":1741225255,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时40分,康希诺生物股票出现波动,股价大幅拉升5.00%。截至发稿,该股报37.800港元/股,成交量52.14万股,换手率0.39%,振幅3.33%。机构评级方面,在所有6家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。康希诺生物股票所在的生物技术行业中,整体涨幅为0.93%。康希诺生物公司简介:许可项目:第三类医疗器械经营;药品生产;药品进出口;药品零售;药品批发;货物进出口;技术进出口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094055abea71f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094055abea71f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06185","BK0239","688185"],"gpt_icon":0},{"id":"2516212625","title":"康希诺生物03月04日遭主力抛售170万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516212625","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516212625?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:38","pubTimestamp":1741081110,"startTime":"0","endTime":"0","summary":"03月04日, 康希诺生物股价跌1.51%,报收35.90元,成交金额4571万元,换手率0.96%,振幅4.66%,量比0.36。康希诺生物今日主力资金净流出170万元,连续3日净流出,上一交易日主力净流出203万元。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为66.67%,平均跌幅为3.92%。该股近5个交易日下跌3.48%,主力资金累计净流入871万元;近20日主力资金累计净流入4828万元,其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174311abe792c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174311abe792c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","06185","BK1161","BK1191","BK1574"],"gpt_icon":0},{"id":"2516651641","title":"全国政协委员、康希诺生物首席科学官朱涛:希望通过政策优化医药创新生态 支持医药创新成果转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2516651641","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516651641?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:20","pubTimestamp":1741022430,"startTime":"0","endTime":"0","summary":"医药创新成果的转化效率,直接关系着人民的生命健康。目前,医药创新成果转化过程较为复杂,涉及科研机构、企业、监管部门等多个主体,现有的部分政策和机制一定程度上制约了成果转化的效率。为此,希望通过政策优化医药创新生态、支持医药创新成果转化,可以在审批流程上进行改进,提高疫苗等新药上市转化效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335164351.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335164351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1191","06185","BK1515","BK1161","BK1574"],"gpt_icon":0},{"id":"2516868398","title":"康希诺:mRNA技术平台可应用于多类生物制品的开发,包括肿瘤领域及免疫治疗也可以是拓展方向","url":"https://stock-news.laohu8.com/highlight/detail?id=2516868398","media":"互动易","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516868398?lang=zh_cn&edition=full","pubTime":"2025-03-03 17:09","pubTimestamp":1740992941,"startTime":"0","endTime":"0","summary":"有投资者向康希诺提问, 贵公司上海康希诺的定位是什么?疫苗+药品是公司唯一壮大的途径,上海康希诺未来是否向创新肿瘤药和创新免疫药方面发展?谢谢。公司回答表示,尊敬的投资人您好,康希诺上海子公司主要为mRNA技术等前沿技术的探索与技术积累转化而设立。mRNA技术平台可应用于多类生物制品的开发,包括肿瘤领域及免疫治疗也可以是拓展方向。现阶段公司将在做好主营业务的基础上进行延展探索。未来如有阶段性进展,将及时分享。谢谢!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303171942a25cddb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303171942a25cddb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1161","06185","BK1191","BK1574","688185"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":0.0969},{"period":"1month","weight":0.0165},{"period":"3month","weight":0.206},{"period":"6month","weight":0.2528},{"period":"1year","weight":0.8945},{"period":"ytd","weight":0.0778}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":-0.0433},{"period":"3month","weight":0.0937},{"period":"6month","weight":0.0787},{"period":"1year","weight":0.2452},{"period":"ytd","weight":0.1027}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.037679},{"month":2,"riseRate":0.833333,"avgChangeRate":0.200805},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.050404},{"month":4,"riseRate":0.714286,"avgChangeRate":0.065279},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.048095},{"month":6,"riseRate":0.5,"avgChangeRate":0.040455},{"month":7,"riseRate":0.5,"avgChangeRate":0.015509},{"month":8,"riseRate":0,"avgChangeRate":-0.182296},{"month":9,"riseRate":0.666667,"avgChangeRate":0.077531},{"month":10,"riseRate":0.5,"avgChangeRate":0.079945},{"month":11,"riseRate":0.666667,"avgChangeRate":0.127077},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.021788}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}